Northland Capital Partners is pleased to announce its appointment as Nomad and Sole Broker to ImmuPharma. ImmuPharma is an AIM quoted pharmaceutical development company focused developing novel medicines with high sales potential in specialist markets with serious unmet need.
Northland Capital Partners has acted as Joint Broker in a US$25,000,000 fund raise for Motif Bio (MTFB.L). The proceeds of the placing will fund the expenses to be incurred in conducting the two Phase 3 clinical trials of iclaprim for the treatment of ABSSSI, including the completion of the REVIVE-1 trial and general working capital.
Northland Capital Partners has acted as Joint Broker in a £4,500,000 fund raise for Ascent Resources (AST.L). The proceeds of the placing will allow the Company to recomplete the Pg-10 and Pg-11a wells, connect the two wells to the existing central treatment station (CPP), refurbish the CPP, provide working capital and repay the £871,510 loan to Henderson Loan Facility.
Northland Capital Partners has acted as Broker in a £3,500,000 fund raise for ImmuPharma (IMM.L). The placing was undertaken to satisfy new institutional demand and broaden its share register and strengthen its financial position to support its general working capital requirements.